MBB Public Markets I LLC Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX)

MBB Public Markets I LLC bought a new position in Royalty Pharma plc (NASDAQ:RPRX) during the second quarter, according to its most recent 13F filing with the SEC. The fund bought 27,114 shares of the biopharmaceutical company’s stock, valued at approximately $715,000.

A number of other large investors have also recently made changes to their positions in RPRX. Versant Capital Management Inc lifted its position in Royalty Pharma by 5,215.0% during the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 1,043 shares during the last quarter. Gladius Capital Management LP acquired a new stake in Royalty Pharma during the second quarter valued at $32,000. Fidelis Capital Partners LLC acquired a new stake in Royalty Pharma in the first quarter valued at approximately $46,000. GAMMA Investing LLC lifted its holdings in Royalty Pharma by 172.5% during the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 1,037 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 655 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Performance

Shares of RPRX opened at $28.38 on Wednesday. Royalty Pharma plc has a 1 year low of $25.20 and a 1 year high of $31.66. The company has a market capitalization of $16.84 billion, a price-to-earnings ratio of 21.18, a PEG ratio of 4.16 and a beta of 0.46. The company’s 50 day simple moving average is $28.00 and its 200 day simple moving average is $27.88. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The firm had revenue of $537.00 million for the quarter, compared to analyst estimates of $600.83 million. During the same quarter last year, the firm posted $0.85 earnings per share. On average, sell-side analysts predict that Royalty Pharma plc will post 4.04 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Friday, August 16th were given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 2.96%. The ex-dividend date was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is 62.69%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on RPRX. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Morgan Stanley boosted their price objective on Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. Finally, The Goldman Sachs Group boosted their price target on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.